Johnson & Johnson to Participate in 38th Annual JP Morgan Health Care Conference
NEW BRUNSWICK, N.J., Dec. 19, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 38th Annual JP Morgan Health Care Conference on Monday, January 13, at the Westin St. Francis in San Francisco. Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices and Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 2:30 p.m. (Pacific Time)/5:30 p.m. (Eastern Time). A subsequent Question & Answer session is scheduled for 3:00 p.m. (Pacific Time)/6:00 p.m. (Eastern Time).
This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
A webcast replay will be available approximately two hours after the live webcast.
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...
United Breast Cancer Foundation (UBCF) is proud to host a heartfelt event dedicated to honor the memory of Audrey Beverly Christy Mastroianni, a remarkable Rhode Island woman who bravely battled breast cancer. The "Gifts of Comfort and Hope" Mattress...
DRI Healthcare Trust (the "Trust") announces the closing of its previously announced preferred securities refinancing, whereby its US$114,760,000 aggregate principal amount of Series A and Series B preferred securities and 6,369,180 warrants were...
